CLINICAL USE

Antineoplastic agent

DOSE IN NORMAL RENAL FUNCTION

3–4 mg/m2 weekly

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 852
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : No data
  • %Excreted unchanged in urine &nbsp &nbsp : 13

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp : 8

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 20–24

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp : Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    5 mL sodium chloride 0.9% per 5 mg vial

    Route

    IV

    Rate of Administration

    1–3 minutes

    Comments

    Can be injected into the tubing of a fast running infusion of sodium chloride 0.9%, glucose 5% or glucose/saline solutions, or directly into a vein Reconstituted solution is stable for 24 hours if stored in a fridge

    OTHER INFORMATION

    Nadir of the WCC occurs 3–5 days after dose with recovery after another 4–5 days Metabolised by cytochrome P450 (in the CYP 3A subfamily). Elimination is primarily biliary (13% excreted in urine in 24 hrs) Vindesine sulphate .
    Tags:

    • Related News

    sorafenib.txt

    tamsulosin.txt